| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Revenues: | ||||||
Total revenues | ||||||
422 | - | - | - | - | - | - |
Operating expenses: | ||||||
Research and development | ||||||
14,048 | 20,385 | 30,067 | 42,846 | 34,504 | 16,777 | 13,832 |
General and administrative | ||||||
9,352 | 12,435 | 17,078 | 15,094 | 13,112 | 6,777 | 5,710 |
Total operating expenses | ||||||
23,400 | 32,820 | 47,145 | 57,940 | 47,616 | 23,554 | 19,542 |
Income (loss) from operations | ||||||
-22,978 | -32,820 | -47,145 | -57,940 | -47,616 | -23,554 | -19,542 |
Other income (expense), net | ||||||
- | - | - | 65 | -386 | -796 | -472 |
Interest income (expense), net | ||||||
- | - | - | - | - | -832 | -444 |
Loss on extinguishment of debt | ||||||
- | - | - | -29 | - | - | - |
Change in fair value of warrant liabilities | ||||||
- | - | - | - | -29 | -36 | 28 |
Total other expense, net | ||||||
-785 | -1,695 | -1,062 | 36 | -357 | - | - |
Consolidated net income (loss) | ||||||
-23,763 | -34,515 | -48,207 | - | - | - | - |
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited | ||||||
-160 | - | - | - | - | - | - |
Loss before income taxes | ||||||
- | - | - | -57,904 | -47,973 | -24,350 | - |
Income tax benefit | ||||||
- | - | - | -49 | - | - | - |
Net income (loss) attributable to aTyr Pharma, Inc. | ||||||
-23,603 | -34,515 | -48,207 | -57,855 | -47,973 | -24,350 | -20,014 |
Accretion to redemption value of redeemable convertible preferred stock | ||||||
- | - | - | - | 15 | 416 | 1,637 |
Net loss per share attributable to common stockholders, basic and diluted | ||||||
- | - | - | - | -47,988 | - | - |
Net loss attributable to common stockholders | ||||||
- | - | - | - | - | -24,766 | -21,651 |
Net loss per share attributable to common stockholders, basic and diluted | ||||||
-7.03 | -16.11 | -26.13 | -2.44 | -3.03 | -29.69 | -28.39 |
Weighted average common stock shares outstanding, basic and diluted | ||||||
3,355 | 2,141 | 1,845 | 23,681 | 15,838 | 834 | 762 |
Collaboration Revenue [Member] | ||||||
Total revenues | ||||||
422 | - | - | - | - | - | - |